CNBC's Angelica Peebles reports on news from Merck.

This is my latest article where I provide predictions of upcoming dividend increases from companies with long-term dividend growth histories. I expect 10 companies to announce their annual increase...

MRK in-licenses a bispecific antibody, based on the same mechanism as SMMT's lead drug, which outperformed its blockbuster drug, Keytruda, in a lung cancer study.

Merck's stock is undervalued, trading at less than 4x expected 2024 revenues, despite strong revenue growth from Keytruda and other drugs. Keytruda's revenue is projected to increase by 70% from 20...

Merck (NYSE: MRK) recently reported its Q3 results, with revenues and earnings exceeding the street estimates. It garnered $16.7 billion in revenue and adjusted earnings of $1.57 per share, compare...

MRK posts better-than-expected third-quarter results. The company lowers its guidance, likely due to the soft sales performance of the Gardasil vaccines.

Merck & Co Inc (NYSE:MRK, ETR:6MK) has topped third-quarter estimates despite flagging sales of its Gardasil jab, diabetes drugs and Covid-19 treatment. Revenue for the three months to September cl...

Merck & Co posted higher-than-expected third-quarter earnings on Thursday on strong sales of its blockbuster cancer treatment Keytruda, but the U.S. drugmaker also flagged a second straight quarter...

Merck reported third-quarter revenue and adjusted earnings that topped expectations. The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its ani...

The drug company had a disastrous second quarter. It doesn't want a repeat performance.

Get a deeper insight into the potential performance of Merck (MRK) for the quarter ended September 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for ...

There's a lot to like here.

TROY, Mich. , Oct. 25, 2024 /PRNewswire/ -- The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Merck & Co. (NYSE: MRK) as its "Stock to Study" and Ba...

Investor focus is likely to be on the sales of Merck's blockbuster oncology medicine, Keytruda, when the company reports third-quarter earnings.

EF Hutton analyst Jason Kolbert initiated coverage of shares of cancer-immunotherapy biotech ImmunityBio with a Buy rating and a $30 price target on Wednesday.